Literature DB >> 24475432

Dose kidney transplant nephrectomy stop disease progression in plasma exchange resistant post transplant hemolytic uremic syndrome? A case report.

Farzaneh Sharifipour1, Abbasali Zeraati1, Seyed Seifollah Beladi Mousavi2, Fatemeh Hayati2, Mohsen Tavazoe2, Marzieh Beladi Mousavi3.   

Abstract

BACKGROUND: Two different case reports, which have been published previously, suggested that bilateral nephrectomy can improve sever and refractory hemolytic uremic syndrome (HUS) in adults without a history of transplantation. At this study, kidney transplant nephrectomy in a patient with sever post transplant HUS was investigated. CASE: Patient was a 55 years old man with a single small size kidney and end-stage renal disease (ESRD). He had received a kidney from an unrelated donor three months before admission. The patient was admitted with fever and acute renal failure. Clinical and laboratory evaluation wereconsistent with sever De novo hemolytic uremic syndrome (HUS). Different therapeutic regimens administered in this patient including intensive plasma exchange, plasma infusion, empirical antibiotics, and high doses of corticosteroid. Although Cyclosporine was changed to Tacrolimus. After 45 days of treatment, patient's condition did not improve and sever thrombocytopenia (10000-15000/µL) developed. Patient was also suffered from severe hypersensitivity reaction (fever, chills, and itching) following each plasma exchange. Kidney transplant nephrectomy was done. However, sever post operativebleedingoccurred.HUS and thrombocytopenia did not improve and patient died two days after operation.
CONCLUSIONS: According to this experience, Kidney transplant nephrectomy may not be an effective treatment and is not recommended in the treatment of severe and refractory post transplant HUS.

Entities:  

Keywords:  Hemolytic Uremic Syndrome; Kidney Transplant; Nephrectomy; Transplantation

Year:  2013        PMID: 24475432      PMCID: PMC3886173          DOI: 10.5812/nephropathol.8944

Source DB:  PubMed          Journal:  J Nephropathol        ISSN: 2251-8363


  21 in total

1.  Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias.

Authors:  Sarah L Allford; Beverley J Hunt; Peter Rose; Samuel J Machin
Journal:  Br J Haematol       Date:  2003-02       Impact factor: 6.998

2.  Post-transplant hemolytic-uremic syndrome.

Authors:  Piero Ruggenenti
Journal:  Kidney Int       Date:  2002-09       Impact factor: 10.612

3.  Development of transplant renal artery thrombosis and signs of haemolytic-uraemic syndrome following the change from cyclosporin to tacrolimus in a renal transplant patient.

Authors:  Ahmet Alper Kiykim; Caner Ozer; Altan Yildiz; Naci Tiftik; Mehmet Senli; Ebru Kelebek; Erdal Doruk; Erdem Akbay
Journal:  Nephrol Dial Transplant       Date:  2004-10       Impact factor: 5.992

Review 4.  Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab.

Authors:  Domenica Caramazza; Gerlando Quintini; Ignazio Abbene; Alessandra Malato; Giorgia Saccullo; Lucio Lo Coco; Rosa Di Trapani; Roberto Palazzolo; Rita Barone; Giuseppina Mazzola; Sergio Rizzo; Paolo Ragonese; Paolo Aridon; Vincenzo Abbadessa; Sergio Siragusa
Journal:  Transfusion       Date:  2010-12       Impact factor: 3.157

5.  Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.

Authors:  W R Bell; H G Braine; P M Ness; T S Kickler
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

6.  Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome.

Authors:  O Oyen; E H Strøm; K Midtvedt; O Bentdal; A Hartmann; S Bergan; P Pfeffer; I B Brekke
Journal:  Am J Transplant       Date:  2006-02       Impact factor: 8.086

7.  Cyclosporine and tacrolimus-associated thrombotic microangiopathy.

Authors:  P T Pham; A Peng; A H Wilkinson; H A Gritsch; C Lassman; P C Pham; G M Danovitch
Journal:  Am J Kidney Dis       Date:  2000-10       Impact factor: 8.860

Review 8.  Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura.

Authors:  P Ruggenenti; M Noris; G Remuzzi
Journal:  Kidney Int       Date:  2001-09       Impact factor: 10.612

9.  De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection.

Authors:  J Waiser; K Budde; B Rudolph; M A Ortner; H H Neumayer
Journal:  Am J Kidney Dis       Date:  1999-09       Impact factor: 8.860

10.  Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders.

Authors:  James N George; Robert D Woodson; Joseph E Kiss; Kiarash Kojouri; Sara K Vesely
Journal:  J Clin Apher       Date:  2006-04       Impact factor: 2.821

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.